
ALLO • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ALLO in your mock portfolio yet.
Allogene Therapeutics is clearly unprofitable, as reflected in its negative EPS and PE ratio. The current earnings profile suggests ongoing cash burn typical of early‑stage biotech, with no visibility on near‑term profitability. This makes the stock highly dependent on future clinical and regulatory milestones rather than current financial strength.
The stock has shown a strong short‑term rebound, rising 36.3% over the last month, and is trading above its 200‑day moving average, which is technically constructive. However, the RSI around 56.55 suggests the stock is neither overbought nor oversold, implying momentum is positive but not extreme. Overall, the technical picture points to a tentative recovery rather than a firmly established uptrend.
Alternative data for Allogene Therapeutics shows modest but not explosive engagement. Web traffic is relatively low and job postings are flat, while social media followings on Twitter/X and LinkedIn are slowly growing. These signals point to a stable but not rapidly expanding level of external interest and hiring activity.
Allogene Therapeutics presents a mixed picture: technically, the stock has shown a short‑term recovery and is trading above its 200‑day moving average, but the company remains deeply unprofitable with limited alternative‑data evidence of accelerating business momentum. The stock appears to be a high‑risk, sentiment‑ and catalyst‑driven biotech play rather than a fundamentally supported investment at this stage.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: